Welcome to our dedicated page for Fulcrum Therapeutics news (Ticker: FULC), a resource for investors and traders seeking the latest updates and insights on Fulcrum Therapeutics stock.
Fulcrum Therapeutics, Inc. (Nasdaq: FULC) is a clinical-stage biopharmaceutical company that reports frequent updates related to its work in genetically defined rare diseases. Company news regularly highlights progress for its lead program, pociredir, an investigational oral small molecule designed to increase fetal hemoglobin (HbF) for the treatment of sickle cell disease (SCD).
Investors and followers of FULC can expect news items covering clinical trial milestones, such as initial and updated data from the Phase 1b PIONEER trial of pociredir in adults with severe SCD. Fulcrum’s releases describe dose-escalation cohorts, changes in HbF levels, markers of hemolysis and anemia, and observations related to vaso-occlusive crises, along with safety and tolerability findings.
Fulcrum also issues corporate and financial announcements, including quarterly financial results, cash runway commentary, and details of public offerings of common stock and pre-funded warrants. Additional news may feature participation in major medical and investor conferences, such as the American Society of Hematology Annual Meeting and the J.P. Morgan Healthcare Conference, where the company presents clinical and preclinical data.
Other updates include disclosures on early-stage programs, such as calmodulin pathway modulators for bone marrow failure syndromes and preclinical data for EED inhibitor candidates in oncology models, as well as routine items like inducement stock option grants under Nasdaq Listing Rule 5635(c)(4). For readers tracking FULC, this news stream provides insight into the evolution of Fulcrum’s pipeline, its clinical development strategy in sickle cell disease, and its broader efforts in gene-expression modulation for rare diseases.
Fulcrum Therapeutics (NASDAQ: FULC) will release its third quarter 2025 financial results on Wednesday, October 29, 2025, before U.S. markets open.
Management will host a conference call and webcast on October 29, 2025 at 8:00 a.m. ET to discuss results and provide a corporate update. Participants must register to receive dial-in details and a unique PIN. An audio webcast will be available on the company’s Investor Relations website and an archived replay will be posted after the live webcast.
Fulcrum Therapeutics (Nasdaq: FULC) will present preclinical data for FTX-6274, an oral EED inhibitor, showing potential activity in castration‑resistant prostate cancer (CRPC).
The poster (ID 2504P) led by Suchi Raghunathan will be shown at ESMO Congress 2025 in Berlin on Oct 18, 2025, 12:00–12:45 PM CEST. Fulcrum noted the data highlight EED inhibition beyond its hematology programs and said a strategic partnership could best advance oncology development. The poster will be posted on Fulcrum’s Publications & Presentations page after congress publication.
Fulcrum Therapeutics (Nasdaq: FULC) announced inducement grants under Nasdaq Listing Rule 5635(c)(4) to new employees on October 6, 2025. The company granted an aggregate of 47,450 non-statutory stock options under its 2022 Inducement Stock Incentive Plan at an exercise price of $9.50 per share (closing price on the grant date).
Each option has a 10-year term and vests over four years: 25% after the first anniversary of employment and then 6.25% quarterly over the following twelve quarters, subject to continued service.
Fulcrum Therapeutics (Nasdaq: FULC), a clinical-stage biopharmaceutical company, has granted inducement stock options to a new employee. The company issued 35,000 stock options with an exercise price of $7.27 per share, matching the closing price on September 8, 2025.
The options, granted under the 2022 Inducement Stock Incentive Plan, have a ten-year term with a four-year vesting schedule. The vesting includes 25% after the first year and 6.25% quarterly over the following three years, contingent on continued employment.
Fulcrum Therapeutics (NASDAQ:FULC), a clinical-stage biopharmaceutical company developing small molecules for rare genetic diseases, has announced upcoming presentations at two major healthcare investment conferences.
The company will participate in the Cantor Fitzgerald 2025 Annual Global Healthcare Conference on September 4, 2025, and the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025. Both events will be held in New York and feature presentations from key executives including CEO Alex Sapir, CFO Alan Musso, and SVP of Early Development Iain Fraser.
One-on-one meetings with management will be available to interested investors through conference representatives.
Fulcrum Therapeutics (Nasdaq: FULC), a clinical-stage biopharmaceutical company, has announced the granting of inducement stock options to new employees. The company issued an aggregate of 36,400 stock options with an exercise price of $6.96 per share, matching the closing price on August 4, 2025.
The options, granted under the 2022 Inducement Stock Incentive Plan, have a ten-year term and follow a four-year vesting schedule. The vesting includes 25% after the first year and 6.25% quarterly over the following three years, contingent on continued employment.
Fulcrum Therapeutics (NASDAQ:FULC) reported Q2 2025 financial results and clinical progress. The company announced promising results from the 12 mg dose cohort of the Phase 1b PIONEER trial for pociredir in sickle cell disease, showing an 8.6% mean increase in fetal hemoglobin and 67% F-cells, with no serious adverse events.
Financial highlights include $214.1 million in cash reserves as of June 30, 2025, extending runway into 2028. Q2 2025 resulted in a net loss of $17.3 million, compared to net income of $55.4 million in Q2 2024. R&D expenses decreased to $13.0 million from $17.3 million year-over-year, while G&A expenses reduced to $6.8 million from $10.2 million.
Fulcrum Therapeutics (NASDAQ:FULC) announced positive results from the 12 mg dose cohort of Phase 1b PIONEER trial for pociredir in sickle cell disease (SCD). The trial demonstrated a significant 8.6% absolute mean increase in fetal hemoglobin (HbF) after 12 weeks of treatment, with 7 of 16 patients achieving HbF levels above 20%.
Key findings include pan-cellular HbF induction with F-cells increasing from 34% to 67%, meaningful improvements in hemolysis markers, and a 0.9 g/dL increase in total hemoglobin. The drug showed encouraging trends in reducing vaso-occlusive crises (VOCs) and maintained a favorable safety profile with no treatment-related serious adverse events.
The study involved 135 adults across multiple cohorts, including 103 healthy subjects and 32 SCD patients, with all treatment-related adverse events being Grade 1.
Fulcrum Therapeutics (NASDAQ:FULC), a clinical-stage biopharmaceutical company, has scheduled a conference call and webcast for July 29, 2025, at 8:00 a.m. ET to present topline results from the 12 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease.
The presentation will feature distinguished speakers including Dr. Sheinei Alan from the Inova Fairfax Adult Sickle Cell Program and Dr. Wally Smith from the VCU Adult Sickle Cell Program, who will join Fulcrum's management team to discuss the findings.
Fulcrum Therapeutics (Nasdaq: FULC), a clinical-stage biopharmaceutical company, has granted inducement stock options to a new employee. The company awarded 130,000 options at an exercise price of $7.02 per share, matching the closing price on July 7, 2025.
The options, granted under Fulcrum's 2022 Inducement Stock Incentive Plan, have a ten-year term with a four-year vesting schedule. The vesting includes 25% after the first year and 6.25% quarterly over the following three years, contingent on continued employment.
FAQ
What is the current stock price of Fulcrum Therapeutics (FULC)?
What is the market cap of Fulcrum Therapeutics (FULC)?
